Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada Genes Chromosomes and Cancer
(Impact Factor: 4.04).
01/2003; 36(1):7-16. DOI: 10.1002/gcc.10132
Conventional cytogenetic studies have shown that osteosarcomas (OSs) are often highly aneuploid, with a large number of both structural and numerical chromosomal alterations. To investigate the complexity of OS karyotypes in detail, we applied spectral karyotyping (SKY) to a series of 14 primary OS tumors and four established OS cell lines. A total of 531 rearrangements were identified by SKY, of which 300 breakpoints could be assigned to a specific chromosome band. There was an average of 38.5 breakpoints identified by SKY per primary tumor. Chromosome 20 was involved in a disproportionately high number of structural rearrangements, with 38 different aberrations being detected. Chromosomal rearrangements between chromosomes 20 and 8 were evident in four tumors. FISH analysis using a 20q13 subtelomeric probe identified frequent involvement of 20q in complex structural rearrangements of OS cell lines. Characterization of the structural aberrations of chromosomes 8 and 17 by use of SKY demonstrated frequent duplication or partial gains of chromosome bands 8q23-24 and 17p11-13. Other chromosomes frequently involved in structural alteration were chromosomes 1 (47 rearrangements) and 6 (38 rearrangements). Centromeric rearrangements often involving chromosomes 1, 6, 13, 14, 17, and 20 were present. Four of the 14 primary OS tumors were characterized by nonclonal changes that included both structural and numerical alterations. In summary, OS tumors have a very high frequency of structural and numerical alterations, compounded by gross changes in ploidy. This intrinsic karyotype instability leads to a diversity of rearrangements and the acquisition of composite chromosomal rearrangements, with the highest frequency of alteration leading to gain of 8q23-24 and 17p11-13 and rearrangement of 20q. These findings suggest that specific sequences mapping to these chromosomal regions will likely have a role in the development and progression of OS.
Available from: PubMed Central
- "The classification of these centromeres according to DAPI banding and SKY image is complicated, therefore in our karyotype characterizations we did not assign them as clear chromosomal markers. The SKY analyses showed that the karyotypes of untreated and scrambled U2OS cells was characterized by high level of structural and numerical chromosomal alterations, a phenomenon which is described in the literature for this cell line . We therefore focused on clear, well defined chromosomal markers, where the involvement of specific chromosomes was confirmed by FISH using whole chromosome painting probes. "
[Show abstract] [Hide abstract]
ABSTRACT: Polyploidy has been recognized for many years as an important hallmark of cancer cells. Polyploid cells can arise through cell fusion, endoreplication and abortive cell cycle. The inner nuclear membrane protein LAP2beta plays key roles in nuclear envelope breakdown and reassembly during mitosis, initiation of replication and transcriptional repression. Here we studied the function of LAP2beta in the maintenance of cell ploidy state, a role which has not yet been assigned to this protein.
By knocking down the expression of LAP2beta, using both viral and non-viral RNAi approaches in osteosarcoma derived U2OS cells, we detected enlarged nuclear size, nearly doubling of DNA content and chromosomal duplications, as analyzed by fluorescent in situ hybridization and spectral karyotyping methodologies. Spectral karyotyping analyses revealed that near-hexaploid karyotypes of LAP2beta knocked down cells consisted of not only seven duplicated chromosomal markers, as could be anticipated by genome duplication mechanism, but also of four single chromosomal markers. Furthermore, spectral karyotyping analysis revealed that both of two near-triploid U2OS sub-clones contained the seven markers that were duplicated in LAP2beta knocked down cells, whereas the four single chromosomal markers were detected only in one of them. Gene expression profiling of LAP2beta knocked down cells revealed that up to a third of the genes exhibiting significant changes in their expression are involved in cancer progression.
Our results suggest that nuclear fusion mechanism underlies the polyploidization induction upon LAP2beta reduced expression. Our study implies on a novel role of LAP2beta in the maintenance of cell ploidy status. LAP2beta depleted U2OS cells can serve as a model to investigate polyploidy and aneuploidy formation by nuclear fusion mechanism and its involvement in cancerogenesis.
Available from: Mirco Fanelli
- "Interestingly, AURK-B is located on chromosome 17p13.1, which has also been found to be amplified in OS (Bayani et al, 2003). This body of evidence has indicated the Aurora kinases as promising candidates to develop targeted drugs. "
[Show abstract] [Hide abstract]
Aurora kinases are key regulators of cell cycle and represent new promising therapeutic targets in several human tumours.
Biological relevance of Aurora kinase-A and -B was assessed on osteosarcoma clinical samples and by silencing these genes with specific siRNA in three human osteosarcoma cell lines. In vitro efficacy of two Aurora kinases-targeting drugs (VX-680 and ZM447439) was evaluated on a panel of four drug-sensitive and six drug-resistant human osteosarcoma cell lines.
Human osteosarcoma cell lines proved to be highly sensitive to both drugs. A decreased drug sensitivity was observed in doxorubicin-resistant cell lines, most probably related to ABCB1/MDR1 overexpression. Both drugs variably induced hyperploidy and apoptosis in the majority of cell lines. VX-680 also reduced in vitro cell motility and soft-agar cloning efficiency. Drug association experiments showed that VX-680 positively interacts with all conventional drugs used in osteosarcoma chemotherapy, overcoming the cross-resistance observed in the single-drug treatments.
Aurora kinase-A and -B represent new candidate therapeutic targets for osteosarcoma. In vitro analysis of the Aurora kinases inhibitors VX-680 and ZM447439 indicated in VX-680 a new promising drug of potential clinical usefulness in association with conventional osteosarcoma chemotherapeutic agents.
Available from: Maria Zielenska
- "An early report sets the frequency of amplification at 7%, and those events only occurred in tumours from adult patients . Other groups have reported frequencies of gain and amplification of MYC at 14–67% [20, 45, 49, 55, 71, 78, 82, 83]. However, other regions of 8q, including 8q23-qter, 8q21.3-8q23, and 8q21 commonly undergo copy number increases as well [20, 49, 55, 77–79, 83, 84], suggesting that other oncogenes located within these bands could have roles in osteosarcoma pathogenesis . "
[Show abstract] [Hide abstract]
ABSTRACT: Osteosarcoma is a primary bone malignancy with a particularly high incidence rate in children and adolescents relative to other age groups. The etiology of this often aggressive cancer is currently unknown, because complicated structural and numeric genomic rearrangements in cancer cells preclude understanding of tumour development. In addition, few consistent genetic changes that may indicate effective molecular therapeutic targets have been reported. However, high-resolution techniques continue to improve knowledge of distinct areas of the genome that are more commonly associated with osteosarcomas. Copy number gains at chromosomes 1p, 1q, 6p, 8q, and 17p as well as copy number losses at chromosomes 3q, 6q, 9, 10, 13, 17p, and 18q have been detected by numerous groups, but definitive oncogenes or tumour suppressor genes remain elusive with respect to many loci. In this paper, we examine studies of the genetics of osteosarcoma to comprehensively describe the heterogeneity and complexity of this cancer.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.